Devroe Eric's most recent trade in Acrivon Therapeutics Inc was a trade of 186,728 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2026 | 186,728 | 186,728 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 14 Feb 2026 | 723 | 74,585 | - | 1.6 | 1,178 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 1.72 per share. | 13 Jan 2026 | 10,000 | 75,308 | - | 1.7 | 17,218 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.24 per share. | 14 Nov 2025 | 613 | 65,308 | - | 2.2 | 1,373 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 14 Aug 2025 | 613 | 65,921 | - | 1.4 | 852 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. | 14 May 2025 | 613 | 66,534 | - | 1.1 | 699 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 140,540 | 140,540 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.42 per share. | 14 Feb 2025 | 724 | 67,147 | - | 5.4 | 3,924 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.92 per share. | 14 Nov 2024 | 613 | 67,871 | - | 7.9 | 4,855 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.02 per share. | 14 Aug 2024 | 613 | 68,484 | - | 7.0 | 4,303 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 17 May 2024 | 10,000 | 69,097 | - | 1.0 | 10,400 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2024 | 10,000 | 86,615 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.36 per share. | 14 May 2024 | 613 | 59,097 | - | 8.4 | 5,125 | Common Stock |
| Acrivon Therapeutics Inc | Devroe Eric | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 90,090 | 90,090 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.40 per share. | 14 Feb 2024 | 723 | 59,710 | - | 3.4 | 2,458 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2023 | 9,225 | 96,615 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.04 per share. | 05 Jun 2023 | 9,225 | 62,883 | - | 1.0 | 9,594 | Common Stock |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 100,150 | 100,150 | - | - | Stock Option (Right to Buy) | |
| Acrivon Therapeutics Inc | Eric Devroe | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 33,383 | 53,658 | - | 0 | Common Stock |